Antibodies taken from alpacas are to be used in a new pandemic flu drug, in a £33 million project led by AstraZenica.

CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

The monoclonal antibody revolution has produced a wave of important new therapeutics, but developing effective antibodies remains elusive for many targets and indications. The discovery and ...

Not all antibodies that bind their intended target also have the right properties to become safe and effective drugs that are easy to manufacture. In traditional antibody drug development, these ...

Originally derived from camelid heavy chain antibodies, single domain or VHH antibodies can bind epitopes that are inaccessible to conventional monoclonal antibodies due to their small size. Because ...

VHH antibodies were first identified in camels in the 1980s, and they have already been used in some therapies to target chronic disease – including cancer and Alzheimer’s.

CEPI is partnering with Astrazeneca plc to advance VHH-based multispecific antibodies targeting influenza, while Harbour Biomed Ltd. has entered into a global strategic collaboration with Astrazeneca ...

Scinai Immunotherapeutics (NASDAQ: SCNI) , announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing P ...

Researchers developed an alpaca-derived antibody that could lead to a cheaper and more effective therapeutic option for the Omicron variant of the novel coronavirus. The team from Kyoto University ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, ...